Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records.
Yan XieBenjamin BoweZiyad Al-AlyPublished in: BMJ (Clinical research ed.) (2023)
The findings of this emulation of a randomized target trial suggest that molnupiravir might have reduced hospital admission or death at 30 days in adults with SARS-CoV-2 infection in the community during the recent omicron predominant era who were at high risk of progression to severe covid-19 and eligible for treatment with molnupiravir.
Keyphrases
- electronic health record
- coronavirus disease
- sars cov
- adverse drug
- healthcare
- phase iii
- study protocol
- emergency department
- respiratory syndrome coronavirus
- phase ii
- clinical trial
- clinical decision support
- mental health
- randomized controlled trial
- early onset
- open label
- combination therapy
- drug induced
- replacement therapy
- double blind
- placebo controlled